CONTEXT: Leptin replacement therapy improves metabolic complications in patients with lipodystrophy and severe hypoleptinemia (SH), but whether the response is related to the degree of hypoleptinemia remains unclear. OBJECTIVE: The aim of the study was to compare efficacy of leptin therapy in familial partial lipodystrophy, Dunnigan variety (FPLD) patients with SH (serum leptin<7th percentile of normal) vs. those with moderate hypoleptinemia (MH; serum leptin in 7th to 20th percentiles). DESIGN, SETTING, AND PATIENTS: We conducted an open-label, parallel group, observational study in 14 SH (mean±sd, serum leptin, 1.9±1.1 ng/ml) and 10 MH (serum leptin, 5.3±1.0 ng/ml) women with FPLD. INTERVENTION: Patients received 0.08 mg/kg·d of metreleptin by twice daily sc injections for 6 months. MAIN OUTCOME MEASURES: The primary outcome variable was change in fasting serum triglycerides. Other secondary variables were fasting plasma glucose and insulin, insulin sensitivity, hemoglobin A1c, and hepatic triglyceride content. RESULTS: Median fasting serum triglycerides decreased from 228 to 183 mg/dl in the SH group (P=0.04) and from 423 to 339 mg/dl in the MH group (P=0.02), but with no difference between the groups (P value for interaction=0.96). Hepatic triglyceride levels similarly declined significantly from 8.8 to 4.9% in the SH group and from 23.7 to 9.2% in the MH group (P value for interaction=0.9). Loss of body weight and body fat occurred in both groups. Fasting glucose, insulin, glucose tolerance, and hemoglobin A1c levels did not change. K value on insulin tolerance test improved slightly in the SH group (0.98 to 1.24%; P=0.01), but not in the MH group (1.1 to 1.27%; P=0.4). CONCLUSION: Metreleptin replacement therapy is equally effective in FPLD patients with both SH and MH in reducing serum and hepatic triglyceride levels, but did not improve hyperglycemia.
CONTEXT: Leptin replacement therapy improves metabolic complications in patients with lipodystrophy and severe hypoleptinemia (SH), but whether the response is related to the degree of hypoleptinemia remains unclear. OBJECTIVE: The aim of the study was to compare efficacy of leptin therapy in familial partial lipodystrophy, Dunnigan variety (FPLD) patients with SH (serum leptin<7th percentile of normal) vs. those with moderate hypoleptinemia (MH; serum leptin in 7th to 20th percentiles). DESIGN, SETTING, AND PATIENTS: We conducted an open-label, parallel group, observational study in 14 SH (mean±sd, serum leptin, 1.9±1.1 ng/ml) and 10 MH (serum leptin, 5.3±1.0 ng/ml) women with FPLD. INTERVENTION: Patients received 0.08 mg/kg·d of metreleptin by twice daily sc injections for 6 months. MAIN OUTCOME MEASURES: The primary outcome variable was change in fasting serum triglycerides. Other secondary variables were fasting plasma glucose and insulin, insulin sensitivity, hemoglobin A1c, and hepatic triglyceride content. RESULTS: Median fasting serum triglycerides decreased from 228 to 183 mg/dl in the SH group (P=0.04) and from 423 to 339 mg/dl in the MH group (P=0.02), but with no difference between the groups (P value for interaction=0.96). Hepatic triglyceride levels similarly declined significantly from 8.8 to 4.9% in the SH group and from 23.7 to 9.2% in the MH group (P value for interaction=0.9). Loss of body weight and body fat occurred in both groups. Fasting glucose, insulin, glucose tolerance, and hemoglobin A1c levels did not change. K value on insulin tolerance test improved slightly in the SH group (0.98 to 1.24%; P=0.01), but not in the MH group (1.1 to 1.27%; P=0.4). CONCLUSION: Metreleptin replacement therapy is equally effective in FPLD patients with both SH and MH in reducing serum and hepatic triglyceride levels, but did not improve hyperglycemia.
Authors: Elif Arioglu Oral; Vinaya Simha; Elaine Ruiz; Alexa Andewelt; Ahalya Premkumar; Peter Snell; Anthony J Wagner; Alex M DePaoli; Marc L Reitman; Simeon I Taylor; Phillip Gorden; Abhimanyu Garg Journal: N Engl J Med Date: 2002-02-21 Impact factor: 91.245
Authors: Kitt Falk Petersen; Elif Arioglu Oral; Sylvie Dufour; Douglas Befroy; Charlotte Ariyan; Chunli Yu; Gary W Cline; Alex M DePaoli; Simeon I Taylor; Phillip Gorden; Gerald I Shulman Journal: J Clin Invest Date: 2002-05 Impact factor: 14.808
Authors: Robert A Hegele; Maria E Kraw; Matthew R Ban; Brooke A Miskie; Murray W Huff; Henian Cao Journal: Arterioscler Thromb Vasc Biol Date: 2003-01-01 Impact factor: 8.311
Authors: Vinaya Simha; Lidia S Szczepaniak; Anthony J Wagner; Alex M DePaoli; Abhimanyu Garg Journal: Diabetes Care Date: 2003-01 Impact factor: 19.112
Authors: Nevin Ajluni; Rasimcan Meral; Adam H Neidert; Graham F Brady; Eric Buras; Barbara McKenna; Frank DiPaola; Thomas L Chenevert; Jeffrey F Horowitz; Colleen Buggs-Saxton; Amit R Rupani; Peedikayil E Thomas; Marwan K Tayeh; Jeffrey W Innis; M Bishr Omary; Hari Conjeevaram; Elif A Oral Journal: Clin Endocrinol (Oxf) Date: 2017-03-27 Impact factor: 3.478
Authors: Yehuda Handelsman; Elif A Oral; Zachary T Bloomgarden; Rebecca J Brown; Jean L Chan; Daniel Einhorn; Alan J Garber; Abhimanyu Garg; W Timothy Garvey; George Grunberger; Robert R Henry; Norman Lavin; Carmen D Tapiador; Christian Weyer Journal: Endocr Pract Date: 2013 Jan-Feb Impact factor: 3.443